Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1994-9-6
|
| pubmed:abstractText |
An in vitro model was developed that allowed the analysis of hepatitis B virus-specific cytotoxic T lymphocyte responses in patients suffering from acute and chronic hepatitis B virus infections. Since virus-specific cytotoxic T lymphocytes recognize endogenously synthesized and processed antigen only when it is presented in the context of autologous HLA class I molecules and since hepatitis B virus does not infect human cells in vitro, a panel of recombinant vaccinia viruses was constructed to induce the expression of hepatitis B virus envelope and nucleocapsid proteins in cultured primary cells or cell lines derived from the patients to be studied. In order for a cytotoxic T lymphocyte response to be detectable with the currently available techniques, a sufficient number of activated cytotoxic T lymphocytes is required. To meet this requirement, lymphocytes freshly isolated from venous blood were stimulated in vitro with recombinant vaccinia-infected and formaldehyde-fixed autologous T lymphoblasts. The presence of hepatitis B virus-specific cytotoxic T lymphocytes, amplified and activated during this induction culture, was demonstrated in a microcytotoxicity assay using 51Cr-labeled, recombinant vaccinia-infected Epstein-Barr virus-immortalized, autologous B lymphocytes as target cells. Using this in vitro model, we were able to demonstrate the presence of hepatitis B virus envelope- and nucleocapsid-specific cytotoxic T lymphocytes in venous blood from one subject who had recently recovered from an acute hepatitis B virus infection and in three patients suffering from chronic hepatitis B virus infections. No hepatitis B virus-specific cytotoxic T lymphocytes activity was discernible in the venous blood from two vaccine recipients.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0168-8278
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
514-23
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8051391-Acute Disease,
pubmed-meshheading:8051391-Adult,
pubmed-meshheading:8051391-Antibody Specificity,
pubmed-meshheading:8051391-Capsid,
pubmed-meshheading:8051391-Cell Line,
pubmed-meshheading:8051391-Cells, Cultured,
pubmed-meshheading:8051391-Chronic Disease,
pubmed-meshheading:8051391-Genetic Vectors,
pubmed-meshheading:8051391-HLA Antigens,
pubmed-meshheading:8051391-Hepatitis B,
pubmed-meshheading:8051391-Hepatitis B Vaccines,
pubmed-meshheading:8051391-Hepatitis B virus,
pubmed-meshheading:8051391-Humans,
pubmed-meshheading:8051391-Male,
pubmed-meshheading:8051391-Middle Aged,
pubmed-meshheading:8051391-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:8051391-Vaccines, Synthetic,
pubmed-meshheading:8051391-Viral Envelope Proteins
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection.
|
| pubmed:affiliation |
Department of Clinical Chemistry, University of Gent, Belgium.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|